"If patients have one feature, that is bad, and if they have two or more, that is really bad," he said. "Regardless of ...

Arcellx, Inc. advances anito-cel CAR-T therapy for relapsed/refractory multiple myeloma. Click for ACLX pivotal trials, FDA ...

AbbVie has acquired global rights to the lead pipeline asset of Ichnos Glenmark Innovation (IGI), the cancer and autoimmune disease candidate ISB 2001, through an exclusive licensing agreement that ...

AbbVie will be gaining rights to IGI Therapeutics’ lead candidate for oncology and autoimmune diseases in an exclusive ...

Gail Whiteford battled for four years to get the diagnosis with symptoms like back ache, excessive urinating, blood in her urine, earache, cough and mucus being treated with antidepressants in 2021.

A panelist highlights promising early-phase trial data on trispecific antibodies targeting multiple myeloma antigens and CD3, emphasizing their high response rates, manageable safety profiles, and ...

Coach Mike Shields, a Central Texas coaching veteran and Reicher alum, has died after battling cancer. He led with faith, ...

Panelists discuss how the CEPHEUS trial demonstrated that quadruplet therapy (daratumumab, bortezomib, lenalidomide, and dexamethasone) significantly improved minimal residual disease negativity rates ...

PDUFA date nears for GSK plc’s Blenrep (belantamab mafodotin), the U.S. FDA’s Oncologic Drugs Advisory Committee will decide July 17 on whether available data justify the return to market of the ...

In an interview with Moneycontrol on July 14, Glenn Saldanha, Chairman and Managing Director of Glenmark, discussed the ...

Glenmark’s outlicensing deal with AbbVie for a novel drug for blood cancer under development sets a new course for the ...

GSK has been enjoying regulatory momentum in recent months as it works to bring its antibody-drug conjugate (ADC) Blenrep ...